Get the Daily Brief
Latest Biotech News
Triana raises $120M to advance molecular glue program
Triana Biomedicines closed an oversubscribed $120 million Series B to advance TRI‑611 and its molecular glue degrader platform toward clinical proof of concept. The financing was led by Ascenta...
Semaglutide fails to reduce CNS inflammation — Alzheimer’s readouts confirm
New data from phase 3 Evoke and Evoke+ trials showed oral semaglutide did not slow cognitive decline in Alzheimer’s disease, and translational studies reported the drug’s peripheral...
ACIP scraps universal hepatitis B birth dose: parents to consult clinicians
The CDC’s Advisory Committee on Immunization Practices (ACIP) voted to remove the universal recommendation that all newborns receive the hepatitis B vaccine immediately after birth. ACIP passed...
Makary ally Høeg named CDER chief – agency churn expected
Tracey Beth Høeg was named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), marking another leadership change amid ongoing agency turmoil. Høeg, a physician and...
Praxis stops pivotal seizure study early – efficacy triggers readout
Praxis Precision Medicines halted its registrational-phase EMBOLD trial of relutrigine in developmental and epileptic encephalopathies after an interim analysis showed strong efficacy. The early...
Freenome moves to public markets via $330M SPAC – commercialization planned 2026
Freenome announced a merger with a SPAC that will provide roughly $330 million in gross proceeds, including a committed $240 million PIPE from institutional investors. The company plans to use the...
Triana closes $120M Series B to push molecular glue degrader into clinic
Triana Biomedicines closed an oversubscribed $120 million Series B to advance TRI-611, a molecular glue degrader targeting ALK-driven non–small cell lung cancer, toward clinical proof-of-concept....
Natera acquires Foresight to expand MRD sensitivity and lymphoma reach
Natera agreed to acquire Foresight Diagnostics for $275 million up front with up to $175 million in contingent payments tied to revenue and reimbursement milestones. The deal brings Foresight’s...
Ginkgo wins $47M DOE contract to automate high-throughput phenotyping at PNNL
Ginkgo Bioworks secured a four‑year, $47 million contract to design and integrate an automated phenotyping platform for Pacific Northwest National Laboratory (PNNL). The system will automate...
Terray hits BMS milestone – AI-backed discovery validates EMMI platform
Terray Therapeutics reported it reached a discovery milestone under its multi-target collaboration with Bristol Myers Squibb, demonstrating its Experimentation Meets Machine Intelligence (EMMI)...
Gene‑therapy programs face regulatory headwinds – UniQure, Denali update timelines
Two regulatory actions this week signaled growing scrutiny on gene‑therapy development. UniQure said FDA feedback indicates its Huntington’s gene therapy AMT‑130 will likely face a longer, more...
Biopharma funding normalizes; $1B+ takeouts accelerate in targeted therapy areas
Biopharma financing through November shows a reversion toward normalized activity after pandemic-era volatility, with November’s $9.94 billion across 96 transactions trailing October but...
ACIP drops universal hepatitis B birth dose: panel rewrites newborn guidance
The CDC’s Advisory Committee on Immunization Practices voted to remove the standing universal recommendation that all newborns receive the hepatitis B vaccine within hours of birth. The 8–3 vote...
FDA upheaval: Høeg named CDER chief as mRNA coalition warns of agency turmoil
Tracey Beth Høeg, a physician and epidemiologist with prior critiques of COVID‑19 vaccine policy, was appointed acting director of the FDA’s Center for Drug Evaluation and Research. The move marks...
Freenome to go public via $330M SPAC — liquid biopsy developer eyes 2026 launch
Freenome announced a SPAC merger expected to deliver roughly $330 million in proceeds, backed by a $240 million PIPE from institutional healthcare investors. The Bay Area developer is preparing...
Natera expands MRD footprint: Foresight buy aims to boost lymphoma ctDNA testing
Natera completed its acquisition of Foresight Diagnostics in a deal structured for $275 million up front with up to $175 million in earnouts, pairing Foresight’s phased‑variant PhasED‑Seq MRD...
Crescent inks two‑way Kelun pact — PD‑1/VEGF bispecific program set for parallel US‑China readouts
Crescent Biopharma struck a bilateral deal with Sichuan Kelun‑Biotech to generate parallel datasets for its PD‑1/VEGF bispecific CR‑001 and to test combination strategies with antibody‑drug...
Praxis halts pivotal seizure trial early for efficacy — relutrigine draws investor focus
Praxis Precision Medicines stopped its Phase 2/3 EMBOLD study in developmental and epileptic encephalopathies early after an interim analysis showed strong efficacy for the sodium‑channel...
Bristol Myers extends Breyanzi label: CAR‑T cleared for marginal zone lymphoma
Bristol Myers Squibb received regulatory approval to expand the indication for its CAR‑T therapy Breyanzi to include third‑line marginal zone lymphoma, marking the first CAR‑T approval for this...
Syntax Bio publishes CRISPR Cellgorithm: programmable control trims stem‑cell timelines
Syntax Bio reported research in Science Advances on its Cellgorithm platform, a CRISPR‑based system that programs gene activity in human stem cells to accelerate and standardize differentiation....